Liviniti’s 15 Years of Pharmacy Benefit Innovation Have Saved Employers $2 Billion – The Healthcare System Still Hasn’t Caught Up.

American healthcare has a tendency to create a specific type of organization that grows in size, becomes opaque, and eventually becomes so ingrained in the system’s plumbing that no one really expects it to change. These days, pharmacy benefit managers—the businesses that stand between insurers, drug manufacturers, and employers who cover their employees’ prescription costs—are precisely that kind of organization.

The three biggest PBMs have operated with a studied opacity for the majority of their existence, collecting rebates from pharmaceutical companies, keeping a portion, and passing along savings that employers were unable to fully verify because they were never shown the underlying numbers. For the PBMs, the business plan was a huge success. For everyone else, it was a source of long-lasting annoyance and subtly enormous expense.

In this situation, Liviniti, which was established in 2011 as Southern Scripts out of Natchitoches, Louisiana, made the somewhat radical choice to just tell employers the truth. All of the rebates were successful. Every discount is given back to the customer. Real pricing, complete data access, and no spread. When co-founder and CEO LeAnn Boyd introduced the pass-through model, it wasn’t a novel idea, but it was more difficult to implement it at scale and maintain it over the course of fifteen years in an industry that had every financial incentive to turn a blind eye. and less common than it ought to have been.

The fact that one million lives were served in 2026 is a noteworthy accomplishment, not because it is remarkable on its own but rather because of the effort required to get there. The mergers, vertical integration tactics, and pharmacy chain absorption that formed the pharmacy benefit giants did not support this business. Liviniti expanded by persuading employers that transparency was something to be trusted, one benefits decision at a time. In the beginning, this required brokers and consultants to adopt a model that upended the rebate-sharing agreements that had long been a standard component of the industry’s distribution channel compensation. There were undoubtedly some awkward conversations.

In terms of structural opacity, the PBM industry’s standard operating procedure has been compared to the financial services sector prior to the implementation of fee disclosure regulations; these comparisons seem a little unfair until you look at the numbers. In the past, employers who sponsored drug benefit plans for their employees had little insight into what they were really paying for, how much the drugs actually cost, and where the difference between those two numbers was going. For a long time, spread pricing—the practice of charging employers more for a medication than the PBM actually paid—was not only widespread but practically undetectable. Looking back at how long this lasted, there’s a sense that the industry’s ability to enforce the norm through sheer information asymmetry was the only logic that ever supported it.

The more recent development of what began as a pricing philosophy is represented by Liviniti’s clinical tools, such as RxCompass, a navigation platform intended to direct members toward less expensive options for specialty and brand medications. Additionally, the company developed a clinical pharmacy residency program that Boyd says prepares the next generation of pharmacists for leadership in the benefit management industry, and it launched RxWatchtower for member transition support. It is genuinely unclear if these tools will be able to address the larger issue of affordability. Particularly, the cost of specialty drugs keeps rising in ways that no single PBM’s procurement strategy can completely offset. However, when those expenses are incurred, the difference between having and not having data is the difference between guessing and negotiating.

In a way, the federal PBM transparency reforms that were signed into law in January 2026 served as confirmation for Liviniti and the larger case the company had been making for fifteen years. Days prior to the legislation’s passage, Boyd spoke at the Transparency-Rx virtual press conference, promoting changes that Liviniti had been voluntarily implementing since its founding. Pushing for rules that you already follow is an odd position to be in, but it illustrates how slowly institutional change occurs in a sector where the incentives of the incumbents are measured in billions.

There’s something subtly educational about the timeline when you watch a company like Liviniti navigate its anniversary year. For the regulatory environment to start catching up with a model that was clearly better for payers and patients from the beginning, it took fifteen years of proven results, including a million lives, hundreds of millions in employer savings, and a Modern Healthcare Innovators award. Anyone who has attempted to alter any aspect of the healthcare system will attest to the fact that it remains unchanged due to the overwhelming evidence. When the alternative is no longer viable, it moves. That time may finally, albeit belatedly, be coming for pharmacy benefit management.